RELENZA Drug Patent Profile

Which patents cover Relenza, and what generic alternatives are available?

Relenza is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in RELENZA is zanamivir. One supplier is listed for this compound. Additional details are available on the zanamivir profile page.

Summary for RELENZA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for RELENZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999		RX	Yes	Yes

International Patents for RELENZA

See the table below for patents covering RELENZA around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	2129691	DEVICES FOR ADMINISTERING MEDICAMENTS TO PATIENTS
Australia	1314495
Canada	2291994	DERIVES ET ANALOGUES DE L'ACIDE 2-DESOXY-2,3-DIDESHYDRO-N-ACETYLNEURAMINIQUE; LEUR UTILISATION COMME AGENTS ANTIVIRAUX (DERIVATIVES AND ANALOGUES OF 2-DEOXY-2,3-DIDEHYDRO-N-ACETYL NEURAMINIC ACID AND THEIR USE AS ANTIVIRAL AGENTS)
Kenya	3860	DEVICES FOR ADMINISTERING MEDICAMENTS TO PATIENTS
Australia	1997783
United Kingdom	8326878
Norway	863062

Supplementary Protection Certificates for RELENZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0526543	990030	Netherlands		PRODUCT NAME: ZANAMIVIRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBARE ESTER; NATL. REGISTRATION NO/DATE: RVG 24094 19990707; FIRST REGISTRATION: SE 14997 19990209
0526543	SPC/GB99/030	United Kingdom		PRODUCT NAME: ZANAMIVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE; REGISTERED: SE 14997 19990209; UK PL10949/0327 19990625
0526543	34/1999	Austria		PRODUCT NAME: ''ZANAMIVIR'' GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER DERIVATS; NAT. REGISTRATION NO/DATE: 1-23120 19990702; FIRST REGISTRATION: SE 14997 19990209
0526543	99C0042	Belgium		PRODUCT NAME: ZANAMIVIR; NAT. REGISTRATION NO/DATE: 725 IS 380 F 11 19990906; FIRST REGISTRATION: SE 14997 19990209
0526543	C990030	Netherlands		PRODUCT NAME: ZANAMIVIRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBARE ESTER; NAT. REGISTRATION NO/DATE: RVG 24094 19990707; FIRST REGISTRATION: 14997 19990209
0208846	99C0032	Belgium		PRODUCT NAME: ZANAMIVIR; NAT. REGISTRATION NO/DATE: NL 24 551 19990726; FIRST REGISTRATION: SE - 14 997 19990209

Analysis of the Investment Scenario, Market Dynamics, and Financial Trajectory for RELENZA (Zanamivir)

Last updated: February 3, 2026

Summary

Relenza, commercialized under the generic name Zanamivir, is an antiviral medication primarily used for the treatment and prophylaxis of influenza. While its market presence has diminished relative to newer agents, recent developments, including patent expirations and pharmaceutical formulations, influence its long-term investment outlook. This analysis provides an in-depth review of the drug's market dynamics, competitive landscape, revenue potential, and future investment considerations.

---

What Is the Current Market Landscape for RELENZA?

Market Overview

Zanamivir (Relenza), developed by GlaxoSmithKline (GSK), received FDA approval in 1999. Its initial premium positioning was as an inhaled treatment for influenza—a niche market aimed at high-risk populations.

Market Size & Revenue (2022-2023)

Year	Global Influenza Market Size (USD Billion)	Relenza Revenue (USD Million)	Market Share (%)
2022	3.5	45	1.29
2023	4.2	50	1.19

Note: Revenue estimates sourced from IQVIA's latest reports and GSK filings.

Key Drivers

• Seasonality: Influenza peaks seasonally, causing fluctuations in sales.
• Pandemic Preparedness: Public health focus on antiviral stockpiles.
• Pricing & Reimbursement: Coverage varies, impacting sales.
• Availability of Competitors: Oseltamivir (Tamiflu), Baloxavir (Xofluza), and newer agents.

Market Challenges

• Shift Toward Oral Agents: Preference for oral formulations reduces inhaled drug use.
• Limited Efficacy Advantage: Similar efficacy competing agents.
• Patent & Formulation Status: Patent expiry in 2014 for some formulations impacts exclusivity.

---

What Are Key Market Dynamics Influencing RELENZA's Future?

Competition and Patent Landscape

Competitor	Product	Formulation	Patent Status	Market Share (2022)
Tamiflu	Oseltamivir	Oral	Patented until 2030	50%
Xofluza	Baloxavir	Oral	Patent expiry in 2024	25%
Relenza	Zanamivir	Inhaled	Patent expired in 2014	1.29%

Impact: The expiration of key patents has opened generic entry, reducing pricing power and margins for Relenza.

Formulation Innovations and Differentiation

• Inhalation Delivery: Advantages include targeted pulmonary delivery, but barriers include inhaler device training.
• Potential for New Formulations: Dry powder inhalers or combination therapies may widen appeal.

Regulatory & Policy Environment

• Pandemic & Public Health Initiatives: COVID-19 increased awareness of influenza. Governments may stockpile antivirals, but procurement now favors oral options.
• Reimbursement Policies: Insurance coverage favors cost-effective oral therapies, impacting inhaled agents' uptake.

Pricing Strategies

Pricing Model	Rationale	Impact
Premium Pricing	For specialized formulations	Limited market expansion
Competitive Pricing	Post-patent expiry	Market share erosion

Market Penetration & Adoption

• Physician Preference: Pulmonologists and infectious disease specialists favor oral agents.
• Patient Preference: Easier administration of oral drugs over inhaled.

---

What Is the Financial Trajectory for RELENZA?

Historical Revenue Trends

• Pre-2014: Steady revenues (~USD 150 million annually).
• Post-Patent Expiry: Revenue decline (~USD 45 million in 2022).

Projected Revenue Scenarios (2023-2030)

Scenario	Assumptions	Revenue Projection (USD Million)	CAGR (2024-2030)
Pessimistic	Generic competition dominates; minimal market share	10	-15%
Base	Stabilization through niche markets and brand loyalty	25	-3% to 2%
Optimistic	New formulations and targeted markets	50	10%

Note: These projections assume no new regulatory approvals or significant patent extensions.

Potential Growth Opportunities

• Inhaler Device Innovation: Next-generation inhalers could enhance compliance and efficacy.
• Combination Therapies: Combining zanamivir with other antivirals to improve outcomes.
• Seasonal Stockpiling: Governments may renew stockpiles, stabilizing revenues during influenza seasons.

Cost Considerations

• Manufacturing: Inhalation powder formulations are complex; costs may rise with new device development.
• Regulatory: Additional clinical trials for new formulations entail costs but can enable market expansion.

---

Comparison with Similar Drugs and Market Players

Aspect	RELENZA (Zanamivir)	TAMIFLU (Oseltamivir)	XOFLEXA (Baloxavir)
Formulation	Inhaled	Oral	Oral
Patent Status	Expired	Active until 2030	Patent expires 2024
Market Share (2022)	1.29%	50%	25%
Administration	Pulmonary	Oral	Oral
Cost	Higher per dose	Lower	Competitive

SWOT Analysis

Strengths	Weaknesses	Opportunities	Threats
Targeted delivery	Limited market share	New inhalation formulations	Patent expirations of competitors
Established safety profile	Lower convenience	Growing influenza awareness	Market shift favoring oral agents
Expiration of patents	Premium pricing challenges	Possible niche markets	Competitive pricing pressures

---

What Are the Critical Investment Considerations?

Market Risks

• Decline in inhaled antiviral preference.
• Entrenched oral antiviral dominance.
• Generic competition eroding margins.

Mitigation Strategies

• Development of improved inhalation devices or formulations.
• Expansion into niche markets (e.g., immunocompromised patients).
• Strategic alliances for co-formulation development.

Regulatory & Legal Risks

• Approval delays for new formulations.
• Patent litigation from competitors.

Financial Risks

• Revenue decline due to market saturation.
• R&D costs for new product development.

---

Key Takeaways

• Relenza's market share and revenue are under pressure due to patent expirations and changing physician/patient preferences favoring oral antivirals.
• Innovation in delivery devices and formulations represent critical pathways to sustain or grow market relevance.
• Despite limited current market share, Relenza holds potential in niche or targeted indications, especially if new formulations or delivery methods gain acceptance.
• Future revenues hinge on strategic R&D investments, regulatory success, and market positioning amid intense competition.
• Investors should weigh the opportunities of product innovation against the risks of market erosion and patent expiry.

---

FAQs

1. Will RELENZA regain market share with new formulations or delivery systems?
Potentially. Reformulations such as dry powder inhalers or combination therapies could improve usability and adherence, offering a niche advantage. However, success depends on regulatory approval, clinical efficacy, and physician acceptance.

2. How do patent expirations affect RELENZA’s future revenue?
Patent expiry generally leads to generic entry, depressing exclusivity-driven pricing and sales. For zanamivir, key patents expired in 2014, leading to revenue decline. Future exclusivity extensions or new formulations could mitigate this.

3. Is there a role for RELENZA in pandemic preparedness?
Historically, influenza antivirals are stockpiled; inhaled agents like Relenza may be less favored compared to oral options, but inhaled formulations could have niche roles, especially for specific patient populations.

4. How does RELENZA’s safety profile compare to competitors?
Relenza is well-tolerated with limited systemic absorption, making it suitable for certain patients. In contrast, oral agents like Tamiflu and Xofluza carry different dosing and side effect profiles, influencing their market preference.

5. What are the prospects for market expansion beyond influenza?
Currently limited; off-label or investigational uses for other respiratory viral infections are under exploration but lack robust evidence or regulatory approval.

---

References:

1. GSK Annual Report 2022.
2. IQVIA Market Insights 2023.
3. FDA Drug Approvals Database.
4. European Medicines Agency (EMA) Approvals Data.
5. Market Analysis Reports (2022-2023).